AccScience Publishing / TD / Volume 1 / Issue 1 / DOI: 10.36922/td.v1i1.52
Cite this article
20
Download
8
Citations
133
Views
Journal Browser
Volume | Year
Issue
Search
News and Announcements
View All
CASE REPORT

Combined anti-PD1 immunotherapy for patient with advanced pancreatic cancer: A case report

Zhe Jiang1 Hongyan Li1* Fei Li1
Show Less
1 Department of General Surgery, Xuanwu Hospital, Capital Medical University, Beijing 100053, China
Tumor Discovery 2022 , 1(1), 52; https://doi.org/10.36922/td.v1i1.52
Submitted: 16 March 2022 | Accepted: 29 April 2022 | Published: 6 May 2022
© 2022 by the Authors. Licensee AccScience Publishing, Singapore. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )
Abstract

Pancreatic cancer (PC) is a highly lethal malignancy with a dismal 5-year survival rate. The current treatment modalities for the treatment-associated toxicity of immunotherapy-based approaches are limited. Immunotherapy for PC was needed to be further investigated. This report illustrates the combined use of anti PD-1 immunotherapy with other therapeutic strategies for cancer pain. In this case, a patient with PC was treated with surgical resection, chemotherapy, molecular targeted medicine, and anti-PD1 immunotherapy. The survival period of the patient was more than 6 years since diagnosis. Finally, we will present our perspective on the future development of immunotherapy for PC. In a word, this case report sheds lights on information that would be helpful for more rigorous exploration of PC treatments.

Keywords
Pancreatic cancer
Immunotherapy
PD1
Funding
Beijing Municipal Administration of Hospitals’ Youth Program
Top-notch Youth Project of the Supporting Plan for the Construction of High-level Teachers in Beijing-affiliated Universities
Beijing Excellent Talents Training Funding Project
Xuanwu Hospital Huizhi Talent Project
References
[1]

Raimondi S, Maisonneuve P, Lowenfels AB, 2009, Epidemiology of pancreatic cancer: An overview. Nat Rev Gastroenterol Hepatol, 6(12): 699–708. https://doi.org/10.1038/nrgastro.2009.177 

[2]

Klein AP, Brune KA, Petersen GM, et al., 2004, Prospective risk of PC in familial PC kindreds. Cancer Res, 64(7): 2634–2638.

[3]

Amundadottir L, Kraft P, Stolzenberg-Solomon RZ, et al., 2009, Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet, 41(9): 986–990.

[4]

Wolpin BM, Chan AT, Hartge P, et al., 2009, ABO blood group and the risk of pancreatic cancer. J Natl Cancer Inst, 101(6): 424–431. 

[5]

Li D, Yeung SC, Hassan MM, et al., 2009, Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology, 137(2): 482–488. https://doi.org/10.1053/j.gastro.2009.04.013 

[6]

Blackford A, Parmigiani G, Kensler TW, et al., 2009, Genetic mutations associated with cigarette smoking in pancreatic cancer. Cancer Res, 69(8): 3681–3688.

[7]

Moore MJ, Goldstein D, Hamm J, et al., 2007, Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada clinical trials group. J Clin Oncol, 25(15): 1960–1966. https://doi.org/10.1200/jco.2005.23.16_suppl.1

[8]

Sun J, Wan Z, Chen Y, et al., 2020, Triple drugs co-delivered by a small gemcitabine-based carrier for PC immunochemotherapy. Acta Biomater, 106: 289–300. https://doi.org/10.1016/j.actbio.2020.01.039 

[9]

Wu D, Lv J, Zhao R, et al., 2020, PSCA is a target of chimeric antigen receptor T cells in gastric cancer. Biomark Res, 8: 3–16. https://doi.org/10.1186/s40364-020-0183-x

[10]

Gautam SK, Kumar S, Dam V, et al., 2020, MUCIN-4 (MUC4) is a novel tumor antigen in PC immunotherapy. Semin Immunol, 14: 101391–101399. https://doi.org/10.1016/j.smim.2020.101391

[11]

Okusaka T, Furuse J, 2020, Recent advances in chemotherapy for pancreatic cancer: Evidence from Japan and recommendations in guidelines. J Gastroenterol, 55(4): 369–382. https://doi.org/10.1007/s00535-020-01666-y 

[12]

Schizas D, Charalampakis N, Kole C, et al., 2020, Immunotherapy for pancreatic cancer: A 2020 update. Cancer Treat Rev, 86: 102016. https://doi.org/10.1016/j.ctrv.2020.102016

[13]

Tivadar ST, McIntosh RS, Chua JX, et al., 2020, Monoclonal antibody targeting sialyl-di-Lewisa-containing internalizing and noninternalizing glycoproteins with cancer immunotherapy development potential. Mol Cancer Ther, 19(3): 790–801. https://doi.org/10.1158/1535-7163.mct-19-0221

Conflict of interest
The authors report no conflict of interest.
Share
Back to top
Tumor Discovery, Electronic ISSN: 2810-9775, Print ISSN: TBA, Published by AccScience Publishing